183 related articles for article (PubMed ID: 18386762)
1. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study.
Vincent JL; Laterre PF; Decruyenaere J; Spapen H; Raemaekers J; Damas F; Rogiers P; Sartral M; Haentjens T; Nelson D; Janes J
Acta Clin Belg; 2008; 63(1):25-30. PubMed ID: 18386762
[TBL] [Abstract][Full Text] [Related]
2. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.
Martin G; Brunkhorst FM; Janes JM; Reinhart K; Sundin DP; Garnett K; Beale R
Crit Care; 2009; 13(3):R103. PubMed ID: 19566927
[TBL] [Abstract][Full Text] [Related]
3. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
[TBL] [Abstract][Full Text] [Related]
4. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.
Wheeler A; Steingrub J; Schmidt GA; Sanchez P; Jacobi J; Linde-Zwirble W; Bates B; Qualy RL; Woodward B; Zeckel M
Crit Care Med; 2008 Jan; 36(1):14-23. PubMed ID: 18158435
[TBL] [Abstract][Full Text] [Related]
5. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
[TBL] [Abstract][Full Text] [Related]
6. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; Booth FV
Surgery; 2007 Apr; 141(4):548-61. PubMed ID: 17431957
[TBL] [Abstract][Full Text] [Related]
7. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.
Vincent JL; Nadel S; Kutsogiannis DJ; Gibney RT; Yan SB; Wyss VL; Bailey JE; Mitchell CL; Sarwat S; Shinall SM; Janes JM
Crit Care; 2005 Aug; 9(4):R331-43. PubMed ID: 16137345
[TBL] [Abstract][Full Text] [Related]
8. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
[TBL] [Abstract][Full Text] [Related]
9. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
[TBL] [Abstract][Full Text] [Related]
10. Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.
Bertolini G; Rossi C; Anghileri A; Livigni S; Addis A; Poole D
Intensive Care Med; 2007 Mar; 33(3):426-34. PubMed ID: 17325836
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
Barie PS; Hydo LJ; Shou J; Eachempati SR
Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
[TBL] [Abstract][Full Text] [Related]
12. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
Laterre PF; Nelson DR; Macias W; Abraham E; Sashegyi A; Williams MD; Levy M; Levi M; Utterback B; Vincent JL
J Crit Care; 2007 Jun; 22(2):142-52. PubMed ID: 17548026
[TBL] [Abstract][Full Text] [Related]
13. International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.
Sashegyi A; Trzaskoma BL; Nelson DR; Williams MD; Macias W
Curr Med Res Opin; 2006 May; 22(5):1001-12. PubMed ID: 16709322
[TBL] [Abstract][Full Text] [Related]
14. Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
Sadique MZ; Grieve R; Harrison DA; Cuthbertson BH; Rowan KM
Crit Care; 2011; 15(5):R228. PubMed ID: 21943177
[TBL] [Abstract][Full Text] [Related]
15. Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).
Shorr AF; Nelson DR; Wyncoll DL; Reinhart K; Brunkhorst F; Vail GM; Janes J
Crit Care; 2008; 12(2):R45. PubMed ID: 18394162
[TBL] [Abstract][Full Text] [Related]
16. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
Nadel S; Goldstein B; Williams MD; Dalton H; Peters M; Macias WL; Abd-Allah SA; Levy H; Angle R; Wang D; Sundin DP; Giroir B;
Lancet; 2007 Mar; 369(9564):836-843. PubMed ID: 17350452
[TBL] [Abstract][Full Text] [Related]
17. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
Abraham E; Laterre PF; Garg R; Levy H; Talwar D; Trzaskoma BL; François B; Guy JS; Brückmann M; Rea-Neto A; Rossaint R; Perrotin D; Sablotzki A; Arkins N; Utterback BG; Macias WL;
N Engl J Med; 2005 Sep; 353(13):1332-41. PubMed ID: 16192478
[TBL] [Abstract][Full Text] [Related]
18. Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy.
Camporota L; Corno E; Menaldo E; Smith J; Lei K; Beale R; Wyncoll D
Crit Care; 2008; 12(6):R163. PubMed ID: 19094233
[TBL] [Abstract][Full Text] [Related]
19. From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).
Short MA; Schlichting D; Qualy RL
Curr Med Res Opin; 2006 Dec; 22(12):2525-40. PubMed ID: 17265595
[TBL] [Abstract][Full Text] [Related]
20. 90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study.
Decruyenaere J; De Backer D; Spapen H; Laterre PF; Raemaekers J; Rogiers P; Trine H; Sartral M; Haentjens T; Wagner T
Acta Clin Belg; 2009; 64(1):16-22. PubMed ID: 19317237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
